Other Transaction Agreement W911QY2190009

Just-Evotec Biologics, Inc., doing business as Just-Evotec Biologics, has been awarded a $17.9 million other transaction agreement by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to support the production of monoclonal antibody (mAb) countermeasures against COVID-19. The contract will run from July 2020 through February 2022 and will be performed in Seattle, Washington. Under the agreement, Just-Evotec Biologics will leverage its expertise in...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded Astrazeneca Pharmaceuticals LP a $439.2 million Other Transaction Agreement to deliver a "COVID-19" monoclonal antibody therapeutic prototype. Performance will occur in Talleyville, Delaware through August 2022. As part of the larger Joint Project Manager for Medical Countermeasure Systems portfolio addressing chemical and biological threats, this appears to support the development...

This federal contract award, W911QY2190008, was issued by the Joint PEO Chemical and Biological Defense, a subcomponent of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $62,096,250.00 Other Transaction Agreement is for the development of a "COVID-19" Monoclonal Antibody (MAB) Sponsorship Prototype. Resilience Government Services, a technology-focused biomanufacturing company, has previously received federal...

This is a $2,853,184,716.00 COVID-19 contract awarded by the Joint Program Executive Office for Chemical, Biological, Defensive (JPEO-CBD) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract is for the procurement of Sotrovimab monoclonal antibodies, an antiviral medication used to treat COVID-19. The contract does not have a set-aside designation. The prime contractor, Glaxosmithkline, LLC, has a history of federal contract awards and grants, primarily...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Emergent Biosolutions Canada Inc. valued at $34.6 million to support the development of human immune globulin (COVID-HIG) manufactured from human plasma with antibodies to SARS-CoV-2. The contract aims to prevent coronavirus disease (COVID-19) through October 2022. Performance will take place at Emergent Biosolutions Canada Inc.'s facility in Ottawa,...

This is a $23,109,340.68 cost-plus-fixed-fee delivery order awarded to Emergent Manufacturing Operations Baltimore LLC, a for-profit limited liability company manufacturer, by the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. The contract is for the development of a plasma-derived polyclonal antibody-based COVID-19 therapeutic, under the Centers for Innovation in Advanced Development and Manufacturing program. No...

This is a $5,565,000,000.00 Firm Fixed Price definitive contract awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Regeneron Pharmaceuticals Inc. for the production of a COVID-19 therapeutic in support of Operation Warp Speed. The contract has no set-aside and is scheduled for completion by July 31, 2022. Regeneron Pharmaceuticals Inc. is a for-profit manufacturer of goods that has expanded its services from supplying specific pharmaceutical products to large-scale...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive contract valued at approximately $1.4 billion to Eli Lilly and Company. The firm fixed price contract is for the delivery of monoclonal antibody LY-COV555 to address the Coronavirus COVID-19 national interest. Performance will occur at Eli Lilly's facility in Indianapolis, Indiana over an approximately 8 month period concluding in June 2021. No set aside designation or...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $54.5 million other transaction agreement to Inovio Pharmaceuticals, Inc. to support the development of an electroporation device for COVID-19 prototype efforts. Performance will take place in Plymouth Meeting, Pennsylvania over a two-year period concluding in June 2022. The contract was awarded without any set aside designations to the prime contractor Inovio Pharmaceuticals to develop...

This is a definitive contract awarded by the Joint PEO Chemical and Biological Defense, a component of the Department of the Army Acquisition Support Center, to Eli Lilly and Company, a for-profit manufacturer of goods. The $2,105,000,000.00 firm fixed price contract is for the delivery of LYCOV1404 BEBTELOVIMAB, a monoclonal antibody treatment, to support the government's Coronavirus COVID-19 response efforts. The contract has an ultimate completion date of September 30, 2023 and does not...